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Abstract
Background: Gastric neuroendocrine neoplasms (G-NENs) are uncommon, and data on their management is
limited. We here investigated the clinicopathological characteristics, surgical and survival outcomes in G-NENs
among Chinese. Moreover, we will discuss their prognostic value.
Methods: From existing databases of the West China Hospital, we retrospectively identified 135 consecutive
patients who were surgically treated and pathologically diagnosed as G-NENs from January 2009 to August 2015.
Results: This entire cohort comprised 98 males and 37 females, with a median age of 60 years. Twenty-five patients
underwent endoscopic resection, while 110 patients underwent open/laparoscopic surgery. Thirty-nine patients had
neuroendocrine tumor G1 (NET G1), seven patients had neuroendocrine tumor G2 (NET G2), 69 patients had
neuroendocrine carcinoma G3 (NEC G3) and 20 patients had mixed adenoneuroendocrine carcinoma (MANEC). The
median survival was not achieved for both NET G1 and NET G2 versus 19 months (range 3–48) for NEC G3 and 10.
5 months (range 3–45) for MANEC. The 3-year survival rates for stage I, II, III, and IV were 91.1 %, 78.6 %, 51.1 % and
11.8 %, respectively (P < 0.001). As for the prognostic analysis, both surgical margin and the newly updated World
Health Organization (WHO) classification were independent predictors of overall survival (OS).
Conclusions: G-NENs are a kind of rare tumors, and patients with NET G3 and MANEC have unfavorable prognosis
even surgically treated. Moreover, surgical margin and the new 2010 WHO criteria are closely associated with OS for
G-NENs.
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Background
Gastric neuroendocrine neoplasms (G-NENs) are a
heterogeneous group of neoplasms, showing different
clinicopathological characteristics and behaviors, and it
composed of cells containing neuroendocrine secretory
granules in their cytoplasm [1, 2]. G-NENs, with an inci-
dence of 0.3 per 100000 each year, are uncommon,
accounting for only 4 % of all NENs of the body [3, 4].
The incidence of G-NENs has increased dramatically
over the last decades, which may attributed to factors
such as increased clinical and pathological experience in
diagnosing this disease, as well as heightened physician
awareness and increased endoscopic surveillance. Now-
adays, surgical resection undoubtedly remains the mainstay
of the potentially curative treatment for the G-NENs. Thus,
various types of surgical approaches have already been per-
formed for G-NENs, such as traditional open surgery,
endoscopic and laparoscopic resection [5, 6]. Moreover, G-
NENs often have unpredictable biological behaviors. Some
are associated with a very aggressive clinical course, despite
they are clinically silent [7, 8]. Thus, treating G-NENs is
often a challenge for the attending clinicians.
The proper management of NENs is the ability to stratify
patients into prognostic groups. Nevertheless, the prognos-
tic classification of G-NENs has been challenging due to
their rarity. The world Health Organization (WHO) in
2000 classified G-NENs into 3 categories: well differentiated
neuroendocrine tumor, well-differentiated neuroendocrine
carcinoma, and poorly differentiated neuroendocrine car-
cinoma [9]. Successively, the European Neuroendocrine
Tumor Society (ENETS) in 2006 and the Union for Inter-
national Cancer Control and the American Joint Cancer
Committee (UICC/AJCC) in 2010 proposed the tumor-
node-metastasis (TNM) staging system for G-NENs, re-
spectively [10, 11]. The ENETs TNM staging seems work
better in the prognostic stratification for pancreas, while
the UICC/AJCC might be superior to ENENTs for appen-
dix [12, 13]. In 2010, for wider acceptance, the WHO
updated its classification system into four different categor-
ies: neuroendocrine tumor G1 (NET G1), neuroendocrine
tumor G2 (NET G2), neuroendocrine carcinoma G3 (NEC
G3) and mixed adenoneuroendocrine carcinoma (MANEC)
[14]. However, the studies have specifically evaluated G-
NENs using this new classification are rare till now.
To the best of our knowledge, studies on evaluation of
clinicopathological characteristics, surgical outcome and
prognosis for G-NENs with such a large sample in a
single institution are uncommon due to their rarity and
heterogeneity, especially using the newly 2010 WHO
classification. Therefore, we here aimed to explore the
clinicopathological characteristics and surgical outcomes
on the basis of 135 consecutive patients with G-NENs at
our center, as well as to evaluate the prognostic value of
the new WHO criteria.
Methods
Patient selection
The medical records of all consecutive patients with G-
NENs were retrospectively obtained from the West
China Hospital, Sichuan University between January
2009 and August 2015. The Institutional Review Board
and Ethics Committee of the West China Hospital of
Sichuan University deemed that an ethical review was
not needed for this retrospective analysis. Written
informed consent was obtained from all patients. The
inclusion criteria were as follows: (1) Patients were
surgically treated and pathologically diagnosed as hav-
ing primary G-NENs by the pathologists at our institu-
tion. (2) The pathological diagnosis of the G-NENs
considered the typical morphological findings and the
expression of neuroendocrine markers, such as Chromo-
granin A and/or Synaptophysin and so on (the partial
expression of several neuroendocrine markers was consid-
ered as negative expression). The exclusion criteria were
as follows: (1) Patients with G-NENs synchronous with
other malignancies and insufficient medical charts were
excluded. (2) Patients received only radiofrequency ther-
mal ablation and/or transarterial embolization and/or
transarterial chemoembolization due to extensive distant
metastasis. (3) Adenocarcinomas with scattered neuroen-
docrine cells or with a focal neuroendocrine component
cannot be considered as MANEC were excluded. MANEC
diagnosis was confirmed when the characteristics of coex-
istence of exocrine and neuroendocrine components were
identified, with each of them accounting for at least 30 %
of the lesion [14]. TNM staging was evaluated according
to the guidelines published by the AJCC [11]. The tumors
were graded as NET G1, NET G2, NEC G3, and MANEC
following the newly 2010 WHO classification. And the
definition of each grade is as follows: NET G1: mitotic
count < 2/10 high power fields (HPF) and/or Ki-67 index
≤2 %; NET G2: mitotic count 2–20/10 HPF and/or Ki-67
index 3–20 %; NEC G3: mitotic count >20/10 HPF and/or
Ki-67 index >20 % [14].
Surgery and medical treatment
Patients with G-NENs underwent surgical treatment
with curative intent. The surgical procedures included
endoscopic, laparoscopic resection and traditional open
surgery. Computerized tomography (CT) and/or endo-
scopic ultrasonography were performed in all cases
preoperatively to determine tumor location and size,
depth of invasion, local lymphatic metastasis and distant
metastasis. All endoscopic resections were performed by
skilled endoscopic specialists and surgeons. Endoscopic
complete resection is regarded as the absence of residual
tumor tissue macroscopically on endoscopy and micro-
scopically. Patients treated with open or laparoscopic
resection underwent subtotal, total gastrectomy or wedge
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resection. The lesions were preoperatively diagnosed as
the possibility of benign and/or low-grade malignant
gastric NENs, and without any evidence of distant metas-
tasis and a history of epigastrium surgery, had undergone
laparoscopic surgery. Furthermore, multivisceral resection
was performed for tumors that invaded adjacent tissues
and organs. Frozen slices of incisal margin and surgical
specimen were routinely collected during surgery. The
surgery was classified into three categories: R0 (complete
gross and microscopic resection), R1 (microscopic residual
lesions), and R2 resections (the presence of any gross
residua tumors). Adjuvant chemotherapy was recom-
mended for patients with metastatic G-NENs, R1/R2
resection and NEC/MANEC.
Data collection and follow-up
The parameters that were retrospectively reviewed from
their medical charts included age at diagnosis, gender,
location of primary tumor, immunohistochemical stain-
ing, tumor markers, co-morbidity (including diabetes
mellitus, chronic pulmonary disease, cardiovascular,
chronic liver and renal disease), neutrophil-lymphocyte
ratio (NLR), albumin/globulin ratio (A/G ratio), tumor
grade, vascular invasion, tumor TNM stage at diagnosis,
type of surgery, surgical outcome, and survival outcome,
etc. Follow-up was conducted by office visit, telephone
call, or outpatient clinic visit from October 2015 to
November 2015. Abdominal CT and/or endoscopic ultra-
sonography, blood routine examination, and evaluation of
liver and kidney functions were also performed.
Survival and statistical analysis
Overall survival (OS) was defined as the time from the
start of treatment until death from any cause or last
follow-up visit. Measurement data were expressed as
mean ± standard deviation. Differences among groups
were analyzed using analysis of variance for continuous
variables and χ2 test or Fisher’s exact test for categorical
data. Wilcoxon test was used to test ranked data. OS
was calculated using the Kaplan-Meier method and
compared using a log-rank test. Multivariate analyses
using the Cox proportional hazards model were carried
out to identify factors independently associated with
prognosis. Differences with two-sided P < 0.05 indicated
statistical significance. All statistical analyses were per-
formed using Statistical Package for Social Science (SPSS
Inc., Chicago, IL, USA).
Results
Clinicopathological and demographic characteristics
The demographic and clinical characteristics are summa-
rized in Table 1. In total, one hundred thirty-five patients
with G-NENs were identified. This entire cohort com-
prised 98 males and 37 females, with a male-to-female
ration of 2.6. Median age at initial diagnosis was 60 years
(range 28–81), with a mean of 58.2 ± 12.0 years. In pa-
tients reporting main symptoms upon initial presentation,
Table 1 Demographic and clinical characteristics of the patients
with G-NENs (n = 135)
Variables NET G1
(n = 39, %)
NET G2
(n = 7, %)
NEC G3
(n = 69, %)
MANEC
(n = 20, %)
P value
Gender <0.001
Male 19 (48.7) 5 (71.4) 54 (78.3) 20 (100.0)
Female 20 (51.3) 2 (28.6) 15 (21.7) 0 (0.0)
Age, y 53.3 ± 13.0 47.0 ± 13.1 61.0 ± 10.3 62.2 ± 10.5 <0.001
Lesion
diameter, cm
1.2 ± 0.9 2.4 ± 1.8 5.2 ± 1.8 4.7 ± 3.1 <0.001
Hospital stay,
days




U 7 (17.9) 2 (28.6) 36 (52.2) 9 (45.0)
M 29 (74.4) 3 (42.9) 11 (15.9) 2 (10.0)




Multiple 8 (20.5) 1 (14.3) 1 (1.4) 0 (0.0)
single 31 (79.5) 6 (85.7) 68 (98.6) 20 (100.0)
Mucosal ulcer <0.001
Present 10 (25.6) 7 (100.0) 68 (98.6) 19 (95.0)
Absent 29 (74.4) 0 (0.0) 1 (1.4) 1 (5.0)
Co-morbidity* 0.042
Present 5 (12.8) 2 (28.6) 14 (20.3) 9 (45.0)
Absent 34 (87.2) 5 (71.4) 55 (79.7) 11 (55.0)
Anemia 0.643
Yes 5 (12.8) 2 (28.6) 9 (13.0) 3 (15.0)












NLR 2.5 ± 1.5 2.3 ± 1.6 3.0 ± 1.2 3.1 ± 2.1 0.197
A/G ratio 1.5 ± 0.3 1.5 ± 0.2 1.5 ± 0.3 1.6 ± 0.3 0.581
Tumor markers
CEA↑ 2 (5.1) 0 (0.0) 13 (18.8) 3 (15.0) 0.194
AFP↑ 0 (0.0) 0 (0.0) 3 (4.3) 0 (0.0) 0.638
CA19-9↑ 1 (2.6) 0 (0.0) 8 (11.6) 2 (10.0) 0.354
CA125↑ 1 (2.6) 0 (0.0) 2 (2.9) 0 (0.0) 1.000
CA72-4↑ 0 (0.0) 0 (0.0) 2 (2.9) 2 (10.0) 0.217
G-NENs gastric neuroendocrine neoplasms, NET G1 neuroendocrine tumor G1,
NET G2 neuroendocrine tumor G2, NEC G3 neuroendocrine carcinoma G3,
MANEC mixed adenoneuroendocrine carcinoma, U upper third of stomach,
M middle third of stomach, L lower third of stomach; Co-morbidity* including
diabetes mellitus, chronic pulmonary disease, cardiovascular, chronic liver and
renal disease; NLR Neutrophil-Lymphocyte Ratio, A/G ratio albumin/globulin
ratio, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, CA19-9 carbohydrate
antigen 19-9, CA125 cancer antigen 125, CA72-4 cancer antigen 72-4
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84 patients exhibited abdominal pain/discomfort, 21
patients with dysphagia, 6 patients with gastrointestinal
bleeding, 5 patients with heartburn, 1 patient with abdom-
inal mass, and 18 patients were asymptomatic. Tumor
diameters ranged from 0.3 to 14 cm and with a median of
4.0 cm, with an average of 3.8 ± 2.6 cm. There were 39, 7,
69, and 20 patients had NET G1, NET G2, NEC G3 and
MANEC, respectively. The NEC G3 included small cell
and large cell type in 40 and 29 patients, respectively. No
statistical significances were observed with respect to age,
gender, lesion diameter, tumor location, depth of invasion,
lymph node metastasis, vascular invasion and TNM stage
between small cell and large cell type (P > 0.05). In
addition, there were significantly more males than females
with NET G3 and MANEC comparison to NET G1 (P =
0.001, P < 0.001, respectively). NET G1 and NET G2 had
smaller tumor size than that of NEC G3 and MANEC
(NET G1 vs NEC G3, P < 0.001; NET G1 vs MANEC, P <
0.001; NET G2 vs NEC G3, P < 0.001; NET G2 vs
MANEC, P = 0.005), but no significant difference was
noted between NET G1 and NET G2 (P = 0.115). There
were more tumors exhibited mucosal ulcer in NET G2,
NEC G3 and MANEC than that of NET G1 (P < 0.001).
Furthermore, there were statistical significances with
respect to age, co-morbidity, hospital stay and tumor loca-
tion among these four groups (P <0.05). However, the
number of lesions, hemoglobin level, NLR, A/G ratio, and
tumor markers did not differ among the four groups.
Surgical information and medical treatment
All patients were surgically treated in our institution,
and details can be seen in Table 2. Twenty-five pa-
tients underwent endoscopic resection (ER), while 110
patients underwent open/laparoscopic surgery (3 cases
with laparoscopic resection). Patients who underwent
ER had a smaller tumor size than those with open/
laparoscopic surgery (0.7 ± 0.4 cm vs 4.5 ± 2.3 cm P <
0.001). The depth of invasion was mostly T1 for ER
(24/25 vs 15/110 for open/laparoscopic surgery). A
total of 3 patients underwent multivisceral resection, con-
sisting of 2 patients with Gastrectomy + splenectomy, and
1 patient with Gastrectomy + partial hepatectomy. One
hundred fourteen patients underwent R0 resection, and
21 patients had R1/R2 resection (1 and 20 underwent
endoscopic and open/laparoscopic resection, respectively).
Fourteen patients experienced postoperative complica-
tions, such as abdominal infection (n = 2), intestinal ob-
struction (n = 3), alimentary tract bleeding (n = 5), and
pulmonary infection (n = 4). No perioperative death oc-
curred. A total of 10 patients received somatostatin an-
alogues, while 20 patients (MANEC in 7 cases, NEC
G3 in 11 cases) received cytotoxic chemotherapy. The
most common chemotherapy combination regimens
used as first-line therapy included etoposide-cisplatin
(EP regimen, 9 patients), and irinotecan-cisplatin (IP
regimen, 7 patients).
TNM stages and immunohistochemical characteristics
A TNM stage was assigned for each patient according
to the UICC/AJCC Staging Manual (seventh edition
in 2010). Chest and abdominal CT, as well as endo-
scopic ultrasonography were preoperatively performed
to evaluate the depth of invasion and lymph node for
patients who underwent endoscopic resection. There
were 37, 16, 34, and 48 patients from stages T1 to
T4, respectively. A total of 89 patients were patho-
logically confirmed to have invasion of lymph node,
and the number of positive lymph node range from 1
to 42, with a median of 4. Seventeen patients had dis-
tant metastases, and the liver (n = 9, 52.9 %) was the
most common site of distant metastasis. NET G1 was
mostly in stage I/II (92.3 %); but those with NET G2, NEC
G3 and MANEC were mainly in stage III/IV (57.1 %,
94.2 %, and 90.0 %, respectively). The NET G1 had less
patients with vascular invasion than that of NET G2, and
NEC G3 and MANEC (P = 0.032, P < 0.001, and P < 0.001,
Table 2 Surgical and medical treatments used for G-NENs
Variables Mean ± SD
(Numbers/Percentage)
Surgical approaches
Endoscopic resection 25/135 (18.5 %)
Open/Laparoscopic surgery 110/135 (81.5 %)
Types of gastrectomy*
Proximal gastrectomy 38/110 (34.5 %)
Distal gastrectomy 39/110 (35.5 %)
Total gastrectomy 31/110 (28.2 %)
Wedge resection 2/110 (1.8)
Multivisceral resection#
Gastrectomy + splenectomy 2/110 (1.8 %)
Gastrectomy + partial hepatectomy 1/110 (0.9 %)
Surgical margins
R0 114/135 (84.4 %)
R1/R2 21/135 (15.6 %)
Surgical complications
Abdominal infection 2/135 (1.5 %)
Intestinal obstruction 3/135 (2.2 %)
Alimentary tract bleeding 5/135 (3.7 %)
Pulmonary infection 4/135 (3.0 %)
Perioperative death 0/135 (0.0 %)
Postoperative medical treatments
Cytotoxic chemotherapy 20 (14.8 %)
Somatostatin analogs 10 (7.4 %)
G-NENs gastric neuroendocrine neoplasms; *#including the patients who
underwent Open/Laparoscopic surgery
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respectively). With regarding to depth of invasion, lymph
node metastasis, and distant metastasis, significant differ-
ences were noted among four groups (P ≤ 0.001). A total
of 108 patients (80.0 %) stained positive for Chromogranin
A, 100 patients (74.1 %) for Synaptophysin, 29 patients
(21.5 %) for Neuron Specific Enolase, and 63 patients
(46.7 %) for CD56. However, there were no significant
differences among four groups with respect to these
immunohistochemical markers (P > 0.05). Details were
listed in Table 3.
Survival outcomes and prognostic factors
With a median follow-up duration of 22 months
(range, 2-81months), 52 patients died for the entire
cohort. The main causes of the death were tumor
related (76.9 %) and others (23.1 %, including respira-
tory failure, decompensated cirrhosis, stroke, and lung
cancer). The OS rate for the entire cohort was 82.4 %,
59.0 % and 44.2 % at 1, 3 and 5 years, respectively. The 3-
year OS for endoscopic resection was 92.9 %, while 51.4 %
for open/laparoscopic surgery (P = 0.001). No significant
difference was observed in survival between patients with
and without chemotherapy (P = 0.758), as well as those be-
tween small cell and large cell type (P = 0.933). The
subgroup patients with more advanced disease (NEC and
MANEC) showed that these patients with chemotherapy
had no survival benefit in comparison to those without
chemotherapy (P = 0.730). The median survival was not
achieved for both NET G1 and NET G2 versus
22.5 months (range 2–76) for NEC G3 and 12.5 months
(range 3–45) for MANEC in patients with R0 resection. In
those patients who underwent R0 resection, the NET G1
showed significant better OS compared with that of NEC
G3 and MANEC (P < 0.001, and P < 0.001, respectively),
but did not differ between NET G1 and NET G2 (P =
0.162, Fig. 1), as well as those between NEC G3 and
MANEC (P = 0.102). The 3-year survival rate for the pa-
tients stratified by TNM stages I, II, III, and IV were
91.1 %, 78.6 %, 51.1 % and 11.8 %, respectively (P < 0.001,
Fig. 2). The subgroups of patients with stage I and II
obtained better OS than those in stage III and IV, respect-
ively (I vs III, P < 0.001; I vs IV, P < 0.001; II vs III, P =
0.036; II vs IV, P < 0.001), as well as that between stage III
and IV (P < 0.001), while no notable differences were
found between stage I and II (P = 0.692). Moreover, we
have found that patients who underwent R0 resection
had better OS than that of R1/R2 resection (P < 0.001,
Fig. 3), as well as females had greater prognosis than
males (P = 0.029). OS was significantly greater in
patients with lesion diameter ≤4 cm, NLR ≤2.8, and
number of positive lymph node ≤4 (lesion diameter
≤4 cm vs >4 cm, P < 0.001; NLR ≤2.8 vs >2.8, P = 0.011;
Table 3 Pathological and immunohistochemical characteristics in patients with G-NENs (n = 135)
Variables NET G1 (n = 39, %) NET G2 (n = 7, %) NEC G3 (n = 69, %) MANEC (n = 20, %) P value
Depth of invasion <0.001
T1 29 (74.4) 3 (42.9) 4 (5.8) 1 (5.0)
T2 7 (17.9) 0 (0.0) 6 (8.7) 3 (15.0)
T3 2 (5.1) 0 (0.0) 23 (33.3) 9 (45.0)
T4 1 (2.6) 4 (57.1) 36 (52.2) 7 (35.0)
Lymph node metastasis <0.001
N0 36 (92.3) 3 (42.9) 4 (5.8) 3 (15.0)
N1 3 (7.7) 4 (57.1) 65 (94.2) 17 (85.0)
Distant metastasis 0.001
M0 39 (100.0) 5 (71.4) 60 (87.0) 14 (70.0)
M1 0 (0.0) 2 (28.6) 9 (13.0) 6 (30.0)
TNM stage <0.001
I/II 36 (92.3) 3 (42.9) 4 (5.8) 2 (10.0)
III/IV 3 (7.7) 4 (57.1) 65 (94.2) 18 (90.0)
Vascular invasion 0 (0.0) 2 (28.6) 33 (47.8) 8 (40.0) <0.001
Immunohistochemical features
CgA (+) 32 (82.1) 4 (57.1) 57 (82.6) 15 (75.0) 0.367
Syn (+) 29 (74.4) 5 (71.4) 53 (76.8) 13 (65.0) 0.728
NSE (+) 9 (23.1) 2 (28.6) 16 (23.2) 2 (10.0) 0.594
CD56 (+) 16 (41.0) 4 (57.1) 38 (55.1) 5 (25.0) 0.086
G-NENs gastric neuroendocrine neoplasms, NET G1 neuroendocrine tumor G1, NET G2 neuroendocrine tumor G2, NEC G3 neuroendocrine carcinoma G3, MANEC
mixed adenoneuroendocrine carcinoma, TNM tumor-node-metastasis, CgA Chromogranin A, Syn synaptophysin, NSE neuron specific enolase
Shen et al. BMC Gastroenterology  (2016) 16:111 Page 5 of 11
Fig. 1 Overall survival of 114 G-NENs patients after radical resection (stratified by the new 2010 WHO classification). The NET G1 showed
significant better OS compared with that of NEC G3 and MANEC (P < 0.001, and P < 0.001, respectively), but did not differ between NET G1 and
NET G2 (P = 0.162), as well as those between NEC G3 and MANEC (P = 0.102)
Fig. 2 Comparison of overall survival in all patients with G-NENs of different TNM stages. The subgroups of patients with stage I and II obtained
better OS than those in stage III and IV, respectively (I vs III, P < 0.001; I vs IV, P < 0.001; II vs III, P = 0.036; II vs IV, P < 0.001), as well as that between
stage III and IV (P < 0.001), while no notable differences were found between stage I and II (P = 0.692)
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number of positive lymph node ≤4 vs >4, P < 0.001).
The types of surgery, depth of invasion, lymph node
metastasis, number of positive lymph node, distant me-
tastasis, TNM stage, co-morbidity, surgical margin and
the new 2010 WHO classification were significant fac-
tors of the prognosis for patients with G-NENs in the
univariate analysis (P < 0.05). When coming into the
multivariate analysis, only surgical margin and the new
2010 WHO classification were significant. The univari-
ate and multivariate analyses by Cox regression model
are listed in Table 4.
Discussion
Although the annual incidence of G-NENs has been in-
creased globally in recent decades, data on management of
G-NENs has been poorly described, due to their rarity and
with a spectrum of biological behaviors from benign to
malignant. This study has provided comprehensive infor-
mation on the clinicopathological characteristics, surgical
outcome and prognosis of G-NENs with a relative large
sample in a single institution. Moreover, we here discuss
their prognostic predictors. Our results suggested that there
was an obvious preponderance of males and G-NENs with
high-grade (NEC G3 and MANEC) for this cohort. OS was
significantly greater in patients with lesion diameter ≤4 cm,
NLR ≤2.8, number of positive lymph node ≤4, females and
R0 resection. Moreover, surgical margin and the newly
updated WHO classification have been demonstrated to be
closely associated with OS for G-NENs.
As described previously, for NENs, the male-to-female
ratio ranged from 0.7 ~ 1.2 [7, 15, 16], while our results
showed that a male-to-female ration for this cohort was
2.6. This discrepancy in organ distribution and sex
ration may suggest ethnic differences in the development
of NENs. Thus, it is of utmost importance to carry out
further clinical epidemiology researches with bigger
sample and multicentre in China. Distant metastases can
be detectable at the time of diagnosis in 12.9 % of
patients with neuroendocrine tumors [17]. In this study,
a total of 12.6 % patients with G-NENs who underwent
surgery had distant metastasis. Apart from the regional
lymph nodes, the hepatic metastasis was the most common
for neuroendocrine tumors [18], which was in accordance
with ours finding. Generally, NENs were more indolent
than carcinomas, and the symptoms of NENs were nonspe-
cific for many cases [7, 8]; but abdominal pain (51.4 %) was
the most important clinical manifestations [19]. In our
study, 84 patients (62.2 %) exhibited abdominal pain/dis-
comfort, and 18 patients (13.3 %) were asymptomatic.
In order to improve the prognostic classification of the
NENs and to better guide therapeutic strategies, the
WHO updated its classification system in 2010 and
divided G-NENs into NET G1, NET G2, NEC G3 and
MANEC. However, this scheme may be problematic for
classifying NENs on small bioptic specimens due to
tissue may not be sufficient to evaluate Ki-67 index and
count mitoses, and become a major concern for pa-
thologists sometimes. NET G1 predominated in the
Fig. 3 Comparison of survival in all patients with G-NENs of different surgical margins
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Table 4 Univariate and multivariate analysis of factors with os using cox proportional hazards regression modeling
Variables Survival time, months P univariate P multivariate Odds ratio* (95 % CI)
Gender
Male 24.8 ± 18.6
Female 29.4 ± 17.4 0.202
Age, y
≤ 60 26.5 ± 19.4
> 60 25.6 ± 17.1 0.759
Tumor marker
Normal 26.7 ± 18.1
Abnormal 23.9 ± 19.2 0.479
NLR
≤ 2.8 27.2 ± 18.4
> 2.8 24.1 ± 18.7 0.340
Chemotherapy
Yes 26.4 ± 18.6
N0 24.0 ± 16.9 0.576
Types of surgery
Endoscopic 66.0 ± 5.7
Open/Laparoscopic 41.7 ± 3.4 0.001 0.580 0.6 (0.1 ~ 4.2)
Depth of invasion
T1/T2 34.2 ± 19.5
T3/T4 20.8 ± 15.5 <0.001 0.066 2.6 (0.9 ~ 7.2)
Lymph node metastasis
N0 34.4 ± 20.4
N1 21.8 ± 15.6 <0.001 0.277 0.3 (0.0 ~ 2.5)
Number of positive LN
≤ 4 31.8 ± 20.5
> 4 19.9 ± 13.2 <0.001 0.795 0.9 (0.4 ~ 2.0)
Distant metastasis
M0 27.2 ± 18.4
M1 12.9 ± 11.6 0.012 0.497 1.4 (0.5 ~ 4.1)
TNM stage
I/II 35.0 ± 20.4
III/IV 21.5 ± 15.3 <0.001 0.248 3.9 (0.4 ~ 38.5)
Lesions diameter
≤ 4 cm 30.7 ± 19.2
> 4 cm 20.1 ± 15.3 0.001 0.730 1.1 (0.5 ~ 2.4)
Co-morbidity*
Absent 27.9 ± 18.3
Present 19.7 ± 17.0 0.030 0.060 2.0 (0.9 ~ 4.1)
Surgical margin
R0 28.6 ± 18.5
R1/R2 12.6 ± 9.3 <0.001 0.002 3.9 (1.6 ~ 9.1)
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gastrointestinal tract (stomach, rectum, and small intes-
tine) [20, 21]; but our data suggested that NEC G3 pre-
dominated for G-NENs. The NEC G3 was more frequent
in males (male/female ration of 2) with an average age of
65 years and usually located in the cardia [1, 22]. In the
present study, 52.2 % patients with NEC G3 arose in the
upper third of stomach, and male-dominated with a mean
age of 61 years, which was similar to their results. As
described previously, the pancreatic NET G2, NEC G3
and MANEC often had lymph node invasion [23], as well
as distant metastasis. Similarly, we have found that lymph
node metastasis occurred significant more in tumors with
higher-grade. Furthermore, patients with NET G1 had less
cases with vascular invasion than that of NET G2, and
NEC G3 and MANEC (P = 0.032, P < 0.001, and P < 0.001,
respectively) in this study. Of note, NET G1 was mostly in
stage I /II (92.3 %); but those with NET G2, NEC G3 and
MANEC were mainly in stage III/IV (57.1 %, 94.2 %, and
90.0 %, respectively).
Nowadays, surgery should be the initial treatment if
the G-NENs are technically resectable, and with a basic
principle of radical resection without considering grade
and stage [24]. Previous study indicated that patients
with NENs who underwent R0 resection obtained a sta-
tistically longer survival than those with R1/R2 resection
[25], which was similar to ours results. Patients with pal-
liative resection may relieve discomfort from the size of
the metastases/tumors or endocrine symptoms. In some
unresectable NENs, palliative resection of liver metasta-
ses had a longer survival and better symptoms relief
than non-surgical treatment, as previously reported [26].
Partelli et al. reported that patients with liver metastases
benefit from palliative resection when compare to those
who were conservatively treated (median OS: 89 vs
36 months, P < 0.05) [27]. However, whether palliative re-
moval of the primary tumor or distant metastases can
really results in a survival benefit for G-NENs still remains
controversial. Thus, further clinical trial comparing non-
surgical management to palliative resection of tumor/me-
tastases for unresectable G-NENs should be performed.
The surgical approaches differed from tumor location and
size. ER to treat foregut NET has been increasingly pre-
formed in recent years. Jung et al. has demonstrated that
ER of foregut NENs can be safely performed in selected
cases (tumor size < 20 mm, as well as lesions confined to
the submucosal layer) [5]. In our study, the tumor size
was 0.7 ± 0.4 cm for ER, and the depth of invasion was
mostly T1 for ER (24/25 vs 15/110 for open/laparoscopic
surgery). G-NENs who underwent ER had a good progno-
sis with a 3-year OS of 92.9 %. By contrast, G-NENs with
open/laparoscopic surgery had a greater tumor size (4.5 ±
2.3 cm), and with a more aggressive clinical course. Sys-
temic chemotherapy may be used for non-pancreatic
NENs and G-NENs of high-grade or aggressive clinical
course [6, 28]. Chemotherapy had improved the median
survival for G-NENs patients with more advanced disease
[29]. However, the subgroup patients with more advanced
disease (NEC and MANEC) showed that these patients
with chemotherapy had no survival benefit in comparison
to those without chemotherapy in the present study (P =
0.730). This phenomenon could be attributed to the fact
that some patients received different chemotherapy cycles
and regimens; what’s more, only a small number of pa-
tients with NEC and MANEC received chemotherapy in
this study. To date, there were no conclusions regarding
which regimen was the most effective due to rarity of G-
NENS. Therefore, prospective, multicenter, randomized
clinical trials to verify the efficacy of chemotherapy for G-
NENs are still warranted.
To date, limited data concerning prognoses of patients
with primary G-NENs are available, especially stratified
by new 2010 WHO classification. Overall prognosis was
favorable for NENs, and 5-year survival rate ranged from
75 to 85 % [7, 20]. In the present study, patients had an
unfavorable prognosis, with a 5-year OS of 44.2 %. This
phenomenon could be attributed to the fact that the
research consisted of a high proportion of NEC G3 and
MANEC (65.9 %) in this study. In addition, the patients
with malignant NENs had a worse prognosis, with 5-
year survival of 45.9–50.4 % [25, 30]. We have also re-
ported that the median survival was not achieved for
both NET G1 and NET G2 versus 22.5 months (range
2–76) for NEC G3 and 12.5 months (range 3–45) for
MANEC in patients with R0 resection. Survival was sig-
nificant greater in women, which was in agreement with
previous study [7]. Additionally, there was no significant
difference in OS between large cell and small cell type
for G-NENs, which was similar to other report [31]. For
the NENs, several literatures mentioned that tumor
grade, distant metastasis, TNM stage, tumor location
and size, and age were independent predictors for out-
come in univariate or multivariate analysis [7, 23, 32]. In
Table 4 Univariate and multivariate analysis of factors with os using cox proportional hazards regression modeling (Continued)
WHO classification
NET G1/G2 35.6 ± 197
NET G3/MANEC 21.2 ± 15.5 <0.001 0.021 5.4 (1.3 ~ 22.9)
OS overall survival, NLR Neutrophil-Lymphocyte Ratio, CI confidence interval, LN lymph node, Co-morbidity* including diabetes mellitus, chronic pulmonary
disease, cardiovascular, chronic liver and renal disease; WHO World Health Organization, NET G1 neuroendocrine tumor G1, NET G2 neuroendocrine tumor G2, NEC
G3 neuroendocrine carcinoma G3, MANEC mixed adenoneuroendocrine carcinoma
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the present cohort of primary G-NENs, types of surgery,
depth of invasion, lymph node metastasis, number of
positive lymph node, distant metastasis, TNM stage, co-
morbidity, surgical margin and the new 2010 WHO clas-
sification were significant factors of the prognosis for pa-
tients with G-NENs in the univariate analysis (P < 0.05).
However, surgical margin and the new 2010 WHO clas-
sification remained the only independent indicators for
prognosis in the multivariate analysis. It was worth not-
ing that the new 2010 WHO classification may not woke
well in classifying NET G1 and NET G2 into different prog-
nostic categories in the present study, with a similar conclu-
sion by Yang et al. [33] and Kim et al. [31]. As such, further
studies are still needed to evaluate the prognostic value of
the new WHO criteria based on large populations. TNM
stage I and II cross on the Kaplan-Meier curve at 5 years
may be relevant to its’ low-efficacy to stratify G-NENs into
different prognostic group, as well as due to the small num-
ber of patients diagnosed with stage I and II in this study.
The factors such as gender, depth of invasion, lymph node
metastasis, and TNM stages etc., may somehow affect
prognosis, but could not be an independent prognostic
factor with much significance for G-NENs in comparison
to surgical margin and the new 2010 WHO classification.
However, our study had some limitations. Firstly, the
findings should be carefully interpreted due to the small
number of patients and retrospective nature. Furthermore,
we have demonstrated that 2010-WHO classification
works well in stratifying G-NENs into different prognostic
categories; but this scheme is merely a histological classifi-
cation, which may be not sufficient to predict tumor
progression. Thus, further studies are needed to develop
optimal staging system to use. To date, the optimal medi-
cation regimens for gastric NENs have not well been
established yet, including chemotherapy and/or targeted
therapy. Unfortunately, our data cannot provide enough
evidence to support any notions now. Therefore, further
explorations should be carried out, and we believe that
this can bring the benefit of comprehensive treatment for
gastric NENs to clinical practice in the future.
Conclusions
In sum, G-NENs are a kind of rare tumors, and patients
with NET G3 and MANEC have an unfavorable prognosis
even surgically treated. Moreover, we have demonstrated
that the new 2010 WHO classification might be a valuable
tool to stratify G-NENs into different prognostic categor-
ies, combining with surgical margin were meaningful
prognostic factors of G-NENs.
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